This content is relevant for:Medical Biotechnology / Medical Technologies / Healthcare
The federal government in Germany is putting up EUR 300 million to acquire a 23 percent share of biotech company CureVac.
The firm from the southwestern German city of Tübingen is one of the most high-profile enterprises in the world currently researching a vaccine against the coronavirus.
Looking for inside stories on economic developments? Our magazine Markets Germany covers the latest scoops three times per year.
It contains interesting reports, features, and news about Germany as an investment and technology location.